Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 17/20 | 0.79 |
| ▸ | INSR | P06213 | 6/20 | 0.63 |
| ▸ | LYN | P07948 | 4/20 | 0.63 |
| ▸ | EGFR | P00533 | 4/20 | 0.63 |
| ▸ | SRC | P12931 | 3/20 | 0.63 |
| ▸ | LCK | P06239 | 3/20 | 0.63 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.63 |
| ▸ | FLT4 | P35916 | 3/20 | 0.63 |
| ▸ | KDR | P35968 | 3/20 | 0.63 |
| ▸ | FLT3 | P36888 | 3/20 | 0.63 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.63 |
| ▸ | KIT | P10721 | 2/20 | 0.63 |
| ▸ | FLT1 | P17948 | 2/20 | 0.63 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.63 |
| ▸ | RET | P07949 | 2/20 | 0.63 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.63 |
| ▸ | AURKA | O14965 | 2/20 | 0.63 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.63 |
| ▸ | CSF1R | P07333 | 2/20 | 0.63 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3687238 | 1.00 | IGF1R (0.79) | IGF1RINSRLYNEGFRSRC | |
| SCHEMBL3685686 | 1.00 | IGF1R (0.79) | IGF1RINSRLYNEGFRSRC | |
| SCHEMBL1985347 | 0.94 | IGF1R (0.83) | IGF1RINSRLYNEGFRSRC | |
| SCHEMBL1985348 | 0.94 | IGF1R (0.83) | IGF1RINSRLYNEGFRSRC | |
| SCHEMBL1987332 | 0.91 | IGF1R (0.78) | IGF1RINSRLYNEGFRSRC | |
| SCHEMBL1987334 | 0.91 | IGF1R (0.78) | IGF1RINSRLYNEGFRSRC | |
| SCHEMBL1984543 | 0.91 | IGF1R (0.84) | IGF1RINSRLYNEGFRSRC | |
| SCHEMBL1984545 | 0.91 | IGF1R (0.84) | IGF1RINSRLYNEGFRSRC | |
| SCHEMBL1988562 | 0.91 | IGF1R (0.84) | IGF1RINSRLYNEGFRSRC | |
| SCHEMBL1985148 | 0.90 | IGF1R (0.86) | IGF1RINSRLYNEGFRSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7326699-B2 | 4-Amino-5-phenyl-7-cyclobutyl-pyrrolo(2,3-d)pyrimidine derivatives | NOVARTIS AG (CH) | 2008-02-05 | — | — | US | claimed |
| EP-1390369-B1 | 4-AMINO-5-PHENYL-7-CYCLOBUTYL-PYRROLO(2,3-D)PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2005-11-09 | — | — | EP | claimed |
| US-20210369714-A1 | Prevention and Treatment of Osteoarthritis by Inhibition of Insulin Growth Factor-1 Signaling | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-12-02 | — | — | US | disclosed |
| US-7781393-B2 | Methods for inhibiting tumor cell growth | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2010-08-24 | — | — | US | disclosed |
| US-7326699-B2 | 4-Amino-5-phenyl-7-cyclobutyl-pyrrolo(2,3-d)pyrimidine derivatives | NOVARTIS AG (CH) | 2008-02-05 | — | — | US | disclosed |
| EP-1476192-B1 | METHODS AND COMPOSITIONS FOR TREATING HYPERPROLIFERATIVE CONDITIONS | DANA FARBER CANCER INST INC (US) | 2007-04-25 | — | — | EP | disclosed |
| EP-1737493-A2 | INHIBITORS OF INSULIN-LIKE GROWTH FACTOR RECEPTOR -1 FOR INHIBITING TUMOUR CELL GROWTH | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2007-01-03 | — | — | EP | disclosed |
| EP-1390369-B1 | 4-AMINO-5-PHENYL-7-CYCLOBUTYL-PYRROLO(2,3-D)PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2005-11-09 | — | — | EP | disclosed |
| US-20050215564-A1 | Methods and compositions for treating hyperproliferative conditions | DANA-FARBER CANCER INSTITUTE INC. | 2005-09-29 | — | — | US | disclosed |
| WO-2005082415-A2 | INHIBITORS OF INSULIN-LIKE GROWTH FACTOR RECEPTOR-1 FOR INHIBITING TUMOR CELL GROWTH | DANA FARBER CANCER INSTITUTE, INC. (US) | 2005-09-09 | — | — | WO | disclosed |
| US-20040180911-A1 | 4-Amino-5-phenyl-7-cyclobutyl-pyrrolo(2,3-d)pyrimidine derivatives | NOVARTIS AG (CH) | 2004-09-16 | — | — | US | disclosed |
| EP-1390369-A1 | 4-AMINO-5-PHENYL-7-CYCLOBUTYL-PYRROLO(2,3-D)PYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2004-02-25 | — | — | EP | disclosed |
| WO-2002092599-A1 | 4-AMINO-5-PHENYL-7-CYCLOBUTYL-PYRROLO (2,3-D) PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2002-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180911-A1 | 4-Amino-5-phenyl-7-cyclobutyl-pyrrolo(2,3-d)pyrimidine derivatives | TYMP, DPYD, TYMS | IGF1R 3898/4885INSR 2996/4885LYN 2065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.